In the ever-evolving landscape of oncology, the integration of targeted therapies and immunotherapy has emerged as a transformative strategy, particularly in breast cancer. Antibody-drug conjugates (ADCs), celebrated for their precision in deliveringRead More…
On Sept. 12, the Wall Street Journal reported that Gilead was reaching an acquisition agreement of more than $20 billion with Immunomedics to expand its oncology product pipeline, including trodelvy (sacituzumab govitecan),Read More…
Breast cancer is the most common cancer and cause of death among women. About 20% of breast cancers are HER2-positive (IHC3+ or IHC2+/ISH+), and the remaining 80% are HER2-negative. HER2 is aRead More…
On July 18, Immunopharmas, a leading biopharmaceutical company in the field of antibody-drug conjugates, announced that the Biologics License Application (BLA) of its sacituzumab govitecan for the treatment of metastatic triple-negative breastRead More…